Skip to main content
. 2023 May 31;92:104627. doi: 10.1016/j.ebiom.2023.104627

Fig. 7.

Fig. 7

Response of H3N2b to IV AAV9 gene therapy in a GM1 gangliosidosis patient. (a) H3N2b in urine. (b) H3N2b in plasma. (c) H3N2b in CSF. (d) Changes of CSF H3N2b and β-galactosidase activity. The red dash-dotted lines show the cutoffs for normal ranges as derived from ROC curve analysis.